Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TRI

Endevica Bio drug candidate shows success in weight loss in new study


NORTHBROOK, Ill., April 23, 2024 /PRNewswire/ -- Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study.

This latest research solidifies Endevica Bio's status as a world leader in the scientific understanding of the central melanocortin system. The company's proof-of-concept MC4R agonist compound A07D leverages this biological pathway to induce weight loss in DIO rats, both alone and in combination with GLP1s, while allowing the retention of muscle mass.

Additionally, the treatment of A07D was found to provide durable weight loss even after cessation of treatment ? suggesting that this approach avoids the problem of weight loss plateau and weight rebound seen with use of GLP1s alone.

Results from the study support the idea that weight-regulating effects such as those advanced by Endevica Bio to address conditions such as involuntary cancer-related weight loss, can also be harnessed to regulate weight in several disease areas in which excess weight may be detrimental, including diabetes and obesity.

Endevica Bio's goal is to advance this platform throughout 2024, and the company's oral agonist portfolio for obesity-related disorders is on track for Phase 1 studies in early 2025.

Meanwhile, Endevica Bio's most advanced drug candidate in the weight modulation space, TCMCB07 (B07), will be entering Phase 2 studies this summer. ASCO and ESMO guidelines now specify body mass management as a critical piece of cancer care, as increased mass may confer survival benefit and an increase in quality of life in cancer patients. For this reason, B07, which is intended to address involuntary cancer-related mass loss, has the potential to become part of the new standard of care in oncology.

Together, the findings on these sister molecules demonstrate how Endevica Bio's peptide engineering resulted in several drug candidates that may safely address multiple indications related to metabolism,  weight management, and oncology.

"We're thrilled with the research results showing our drug candidate could potentially improve the lives of millions of people who seek to lose weight," said Russell Potterfield, CEO and Executive Chairman of Endevica Bio. "The positive research findings lend additional credence to Endevica Bio's vision of a new treatment paradigm that will both help those suffering from involuntary cancer-related mass loss as well as conditions in which weight loss is beneficial."

Dr. Daniel Marks, Chief Medical Officer of Endevica Bio, agreed. "The elegance of these peptide-based approaches is that we can engineer them to minimize off-target actions," he said. "The potential of these drug candidates is very exciting, and we look forward to exploring additional ways in which these approaches can address some of the most important diseases humanity faces."

About Endevica Bio

Endevica Bio creates first-in-class peptide drug candidates. Endevica Bio's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of important drug targets behind the blood-brain barrier. More information can be found at www.endevicabio.com.

SOURCE Endevica Bio


These press releases may also interest you

at 16:40
Apple Inc. has released the following notice: A Federal Court authorized this Notice. This is not a solicitation from a lawyer. TO: ALL PERSONS OR ENTITIES WHO OR WHICH HELD SHARES OF APPLE INC. ("APPLE" OR THE "COMPANY") COMMON STOCK AS OF THE...

at 16:35
Samsara Inc. ("Samsara") , the pioneer of the Connected Operationstm Cloud, today announced that it will release its financial results for the first quarter of fiscal year 2025, which ends May 4, 2024, after the U.S. market closes on Thursday, June...

at 16:30
Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today reported April monthly trading volume statistics across its global business lines....

at 16:30
SiriusXM is pleased to announce that Jennifer Witz, Chief Executive Officer, will represent the company at the 52nd Annual JP Morgan Global Technology, Media and Communications Conference. The event is scheduled for Tuesday, May 21 at 10:50 am ET...

at 16:28
The Honourable Soraya Martinez Ferrada, Minister of Tourism and Minister responsible for the Economic Development Agency of Canada for the Regions of Quebec, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and...

at 16:22
The Canadian GED test officially ends on Friday, May 3 after decades of serving adult learners pursuing a high school equivalency diploma, which has opened doors to greater careers and academic opportunities. During that time more than 170,000...



News published on and distributed by: